Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Long-Term Deferred Tax (2016 - 2024)

Guided Therapeutics' Long-Term Deferred Tax history spans 5 years, with the latest figure at $23.5 million for Q4 2017.

  • For Q4 2017, Long-Term Deferred Tax fell 20.33% year-over-year to $23.5 million; the TTM value through Dec 2017 reached $23.5 million, down 20.33%, while the annual FY2017 figure was $23.5 million, 20.33% down from the prior year.
  • Long-Term Deferred Tax for Q4 2017 was $23.5 million at Guided Therapeutics, down from $29.4 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $29.4 million in Q4 2016 and bottomed at $23.0 million in Q4 2013.
  • The 5-year median for Long-Term Deferred Tax is $26.5 million (2014), against an average of $26.2 million.
  • The largest annual shift saw Long-Term Deferred Tax rose 14.92% in 2014 before it dropped 20.33% in 2017.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $23.0 million in 2013, then increased by 14.92% to $26.5 million in 2014, then increased by 8.95% to $28.8 million in 2015, then grew by 2.16% to $29.4 million in 2016, then dropped by 20.33% to $23.5 million in 2017.
  • Per Business Quant, the three most recent readings for GTHP's Long-Term Deferred Tax are $23.5 million (Q4 2017), $29.4 million (Q4 2016), and $28.8 million (Q4 2015).